Literature DB >> 24761270

Combined Effects of Ephedrine-Containing Dietary Supplements, Caffeine, and Nicotine on Morphology and Ultrastructure of Rat Hearts.

Christopher E Brown1, Stanley E Trauth1, Richard S Grippo1, Bill J Gurley2, Anne A Grippo1.   

Abstract

Cigarette smokers have an increased risk for coronary artery disease. Nicotine present in cigarettes can adversely affect the cardiovascular system via stimulation of both sympathetic and parasympathetic neurons. Caffeine, another cardiovascular and central nervous system (CNS) stimulant, is commonly found in Ephedra and Ephedra-free dietary supplements. These caffeine-containing supplements also have been linked to cardiovascular toxicities. Although no longer on the U.S market, Ephedra-containing supplements are another source of cardiovascular and CNS stimulants, namely the ephedrine alkaloids. Together caffeine, nicotine, and ephedrine can individually stress the cardiovascular system, and an overlap of these agents is predicted in smokers and dieters. To understand the collective effects of these stimulants on the heart morphology and ultrastructure, rats were exposed to synthetic combinations of nicotine (0.2 mg/kg/day), ephedrine (0-30 mg/kg/day), and/or caffeine (0-24 mg/kg/day) as well as an extract from a caffeine-containing Ephedra supplement (Metabolife 356). After exposure for 3 days, the hearts were removed and examined for hypersensitivity myocarditis and myocardial necrosis. None of the drugs tested alone affected heart tissue morphology, nor were atypical cardiac cells observed. However, in combination, significant interactions were found between caffeine and ephedrine; the interventricular septum was most susceptible, with a significant increase in atypical cardiac cells observed. Nicotine pretreatment caused greater susceptibility to cardiotoxicity associated with combinations of caffeine + ephedrine or Metabolife, particularly in the left ventricle wall. These results indicate that sympathomimetic combinations present in Ephedra supplements may have produced cardiotoxicity reported in consumers of these products. Moreover, the presence of nicotine exacerbates these toxic effects.

Entities:  

Year:  2012        PMID: 24761270      PMCID: PMC3621369          DOI: 10.1089/jcr.2012.0021

Source DB:  PubMed          Journal:  J Caffeine Res        ISSN: 2156-5368


  36 in total

1.  A pharmacodynamic interaction between caffeine and phenylpropanolamine.

Authors:  N J Brown; D Ryder; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

2.  Differential display analysis of gene expression indicates that age-related changes are restricted to a small cohort of genes.

Authors:  M H Goyns; M A Charlton; J E Dunford; W L Lavery; B J Merry; M Salehi; D C Simões
Journal:  Mech Ageing Dev       Date:  1998-03-16       Impact factor: 5.432

3.  Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes.

Authors:  Guoyi Ma; Supriya A Bavadekar; Yolande M Davis; Shilpa G Lalchandani; Rangaswamy Nagmani; Brian T Schaneberg; Ikhlas A Khan; Dennis R Feller
Journal:  J Pharmacol Exp Ther       Date:  2007-04-03       Impact factor: 4.030

4.  A case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteins.

Authors:  Carol Chen-Scarabelli; Siân E Hughes; Giorgio Landon; Peter Rowley; Zuhair Allebban; Noel Lawson; Louis Saravolatz; Julius Gardin; David Latchman; Tiziano M Scarabelli
Journal:  Eur J Heart Fail       Date:  2005-08       Impact factor: 15.534

5.  Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of ephedrine and caffeine.

Authors:  Abraham Nyska; Elizabeth Murphy; Julie F Foley; Bradley J Collins; John Petranka; Reuben Howden; Paul Hanlon; June K Dunnick
Journal:  Toxicol Sci       Date:  2004-11-10       Impact factor: 4.849

6.  Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue.

Authors:  M Suganuma; S Okabe; M Oniyama; Y Tada; H Ito; H Fujiki
Journal:  Carcinogenesis       Date:  1998-10       Impact factor: 4.944

7.  Use of Ephedra-containing products and risk for hemorrhagic stroke.

Authors:  L B Morgenstern; C M Viscoli; W N Kernan; L M Brass; J P Broderick; E Feldmann; J L Wilterdink; T Brott; R I Horwitz
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

8.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.

Authors:  C A Haller; N L Benowitz
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 176.079

9.  Seizure activity and unresponsiveness after hydroxycut ingestion.

Authors:  D R Kockler; M W McCarthy; C L Lawson
Journal:  Pharmacotherapy       Date:  2001-05       Impact factor: 6.251

10.  Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma-huang) as determined by high performance liquid chromatography.

Authors:  B J Gurley; P Wang; S F Gardner
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.784

View more
  2 in total

1.  Safety assessment of the dietary supplement OxyELITE™ Pro (New Formula) in inbred and outbred mouse strains.

Authors:  Isabelle R Miousse; Charles M Skinner; Haixia Lin; Laura E Ewing; Stanley D Kosanke; D Keith Williams; Bharathi Avula; Ikhlas A Khan; Mahmoud A ElSohly; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2017-08-24       Impact factor: 6.023

2.  Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.

Authors:  Charles M Skinner; Isabelle R Miousse; Laura E Ewing; Vijayalakshmi Sridharan; Maohua Cao; Haixia Lin; D Keith Williams; Bharathi Avula; Saqlain Haider; Amar G Chittiboyina; Ikhlas A Khan; Mahmoud A ElSohly; Marjan Boerma; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2018-09-30       Impact factor: 6.023

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.